Table 2.
Univariate overall survival analysis for all the patients
| Characteristic | No. (%) | P value |
|---|---|---|
| Surgery | ||
| CBS | 254 (58.5) | 0.02 |
| MRM | 180 (41.5) | |
| Age | ||
| < 50 | 210 (48.4) | 0.085 |
| ≥ 50 | 224 (51.6) | |
| Menopausal status | ||
| Premenopausal | 214 (49.3) | 0.252 |
| Perimenopausal | 68 (15.7) | |
| Postmenopausal | 152 (35.0) | |
| Pathology | ||
| IDC | 418 (96.3) | 0.635 |
| Lobular | 6 (1.4) | |
| Medullary | 10 (2.3) | |
| T stage | ||
| 1 | 119 (27.4) | 0.012 |
| 2 | 315 (72.6) | |
| N stage | ||
| 0 | 251 (57.8) | 0.029 |
| 1 | 183 (42.2) | |
| Grade | ||
| 1 | 8 (1.8) | 0.480 |
| 2 | 406 (93.5) | |
| 3 | 20 (4.6) | |
| ER | ||
| Positive | 274 (62.0) | 0.061 |
| Negative | 160 (36.9) | |
| PR | 0.006 | |
| Positive | 222 (51.2) | |
| Negative | 212 (48.8) | |
| HER2 | ||
| Positive | 93 (21.4) | 0.592 |
| Negative | 321 (74.0) | |
| Unknown | 20 (4.6) | |
| TNBC | 122 (24.7) | |
TNBC triple negative breast cancer
CBT conservative breast therapy, MRM modified radical mastectomy
IDC infiltrating duct carcinoma, ER estrogen receptor, PR progesterone receptor